OKT3 + gemcitabine + cisplatin

This is a proposed combination therapy that includes **OKT3** (muromonab-CD3), a mouse monoclonal antibody, along with two chemotherapy agents, **gemcitabine** and **cisplatin**. OKT3 historically targeted the CD3 epsilon chain on T cells for preventing organ transplant rejection but was discontinued in 2011. It has also been investigated for potential use in cancer treatment, sometimes in combination with IL-2. The rationale for this specific combination appears to be leveraging OKT3's ability to modulate T cell activity (specifically, potentially inducing proliferation and making certain T cell tumors more susceptible) to enhance the cytotoxic effects of the established chemotherapy agents gemcitabine (an antimetabolite) and cisplatin (a platinum-based DNA-damaging agent). While the provided text suggests OKT3's exploration in cancer, specific clinical trials or approved indications for this exact combination of OKT3, gemcitabine, and cisplatin are not detailed. This combination represents a multi-modal approach combining immunotherapy (OKT3) with traditional chemotherapy (gemcitabine and cisplatin) for cancer treatment.